Crossject Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Public

  • Employees
  • 103

Employees

  • Stock Symbol
  • ALCJ

Stock Symbol

  • Share Price
  • $1.46
  • (As of Friday Closing)

Crossject General Information

Description

CROSSJECT manufactures and markets needle-free drug self-injection system.

Contact Information

Website
www.crossject.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 6 rue Pauline Kergomard
  • 21000 Dijon
  • France
+33 03
Primary Industry
Drug Delivery
Other Industries
Medical Supplies
Stock Exchange
PAR
Vertical(s)
Manufacturing
Corporate Office
  • 6 rue Pauline Kergomard
  • 21000 Dijon
  • France
+33 03

Crossject Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Crossject Stock Performance

As of 13-Nov-2026, Crossject’s stock price is $1.46. Its current market cap is $88.4M with 60.6M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.46 $1.49 $1.23 - $3.10 $88.4M 60.6M 187K -$0.28

Crossject Financials Summary

As of 30-Jun-2026, Crossject has a trailing 12-month revenue of null.

In Thousands,
USD 		TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 141,423 146,721 122,959 219,496
Revenue 0 0 0 157
EBITDA (12,234) (6,923) (8,457) (8,347)
Net Income (16,420) (11,696) (13,845) (9,349)
Total Assets 40,638 35,747 32,849 31,660
Total Debt 21,262 26,368 21,924 20,926
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Crossject Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Crossject‘s full profile, request access.

Request a free trial

Crossject Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
CROSSJECT manufactures and markets needle-free drug self-injection system.
Drug Delivery
Dijon, France
103 As of 2025

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Crossject Competitors (1)

One of Crossject’s competitors is Portal Instruments, a Venture Capital-Backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Portal Instruments Venture Capital-Backed Cambridge, MA
You’re viewing 1 of 1 competitors. Get the full list »

Crossject Patents

  • 398

    Total Documents Applications and Grants

  • Total Patents Families

  • 204

    Granted

  • 8

    Pending

  • Expiring in next 12 mo

Crossject Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
FR-3128874-B1 Hydrocortisone pharmaceutical solution for injection device Active 09-Nov-2021
AU-2022385353-A1 Pharmaceutical hydrocortisone solution for injection device Active 09-Nov-2021
AU-2022385353-B2 Pharmaceutical hydrocortisone solution for injection device Active 09-Nov-2021
US-12773413-B2 Pharmaceutical hydrocortisone solution for injection device Active 09-Nov-2021
US-20240408110-A1 Pharmaceutical hydrocortisone solution for injection device Active 09-Nov-2021 A61K31/573
To view Crossject’s complete patent history, request access »

Crossject Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Crossject Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Crossject‘s full profile, request access.

Request a free trial

Crossject ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Healthcare

Industry

Rank

Percentile

Medical Supplies

Subindustry

Rank

Percentile

To view Crossject’s complete esg history, request access »

Crossject FAQs

  • When was Crossject founded?

    Crossject was founded in 2001.

  • Where is Crossject headquartered?

    Crossject is headquartered in Dijon, France.

  • What is the size of Crossject?

    Crossject has 103 total employees.

  • What industry is Crossject in?

    Crossject’s primary industry is Drug Delivery.

  • Is Crossject a private or public company?

    Crossject is a Public company.

  • What is Crossject’s stock symbol?

    The ticker symbol for Crossject is ALCJ.

  • What is the current stock price of Crossject?

    As of 13-Nov-2026 the stock price of Crossject is $1.46.

  • What is the current market cap of Crossject?

    The current market capitalization of Crossject is $88.4M.

  • Who are Crossject’s competitors?

    Portal Instruments is a competitor of Crossject.

  • What is Crossject’s annual earnings per share (EPS)?

    Crossject’s EPS for 12 months was -$0.28.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process